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ABSTRACT 
Satisfactory spherical pellets were successfully· prepared by the process of 
extrusionlspheronization using the excipient microcrystalline cellulose (IvrCC) as 
pellet-forming material. Nonetheless, the preparation of acceptable round spheres 
is highly dependent upon the attainment of an optimal formulation suited for this 
mcthod or proccssillg. The earlier part of the work has revealed that the MCe 
pellet system containing the active ingredientdiclofenac sodium generally produced 
strongly bonded spheroids which remained intact throughout the dissolution test. It 
may thus be postulated that the pellets behaved as an inert matrix system. 
The effecl of some excipients on the pellet quality and physical properties of 
diclofenac sodium-containing pellets was investigated. Certain disintegrants used 
, 
were fot~d to have a marked influence on the quality of the pellets. In addition, 
rapid pellet disintegration and dissolution were observed for the soybean oil-
formulated pellets, suggesting the potential of soybean oil as a disintegrating agent 
in pellet dosage form. However, when two other model drugs of varying aqueous 
solubilities, namely paracetamol and artemisinin, were separately incorporated into 
the soybean oil-containing formulations and compared, differences in the physical 
characteristics of the pellets such as disintegration and in vitro drug release were 
observed. The artemisinin-formulated pellets did not disintegrate and at the same 
time showed a considerably slower dissolution release rate than the pellets 
containing either diclofenac sodium or paracetamol, which are of higher aqueous 
solubilities. Since the former preparation exhibited no disintegration and produced 
an in vitro dissolution profile characteristic of sustained release products, it is 
apparent that the incorporated soybean oil failed to act as a disintegrant in the 
;! 
evident that both fast- and slow-release spherical pelleted products can be prepared 
via the extrusion/spheronization technique. 
In vivo evaluation of the artemisinin-containing preparation in five healthy human 
subjects, produced relatively uniform plasma concentration versus time profiles that 
were reflective of a slow and sustained rate of absorption. Moreover, the 
preparation showed a comparable extent of absorption than that of the drug 
administered as an aqueous suspension. Plasma concentrations of the drug wer~ 
determined using a developed HPLC method. A satisfactory correlation was 
obtained between the in vitro dissolution rate measurements and its in' vivo 
pharmacokinetic findings. 
ABSTRAK 
Pelet~pelet yang berbentuk sfera telah berjaya disediakan melalui proses 
ekstrusi/sferonisasi dengan menggunakan mikrokristalin selulosa sebagai bahan 
pembentuk pelet. Walau bagaimanapun, penyediaan sfera yang baik sang at 
hc:rr~,HlruJlE kerada remerolehan suatu formulasi optimum yang padan akan proses 
tersebut. Kajian awal telah menunjukkan bahawa sistem pelet mikrokristalin 
selulosa yang mengandungi ramuan aktif diclofenac sodium, pada amnya 
menghasilkan sferoid yang mempunyai ikatan kuat sehingga bentuknya masih kekal 
semasa proses pemelarutan. Dengan ini, boleh dikatakan bahawa pelet tersebut 
bertindak sebagai sistem matriks lengai. 
Kesan ~berapa eksipieri ke atas kualiti dan ciri-ciri fizikal pelet yang mengandungi 
dic10fenac sodium telah dikaji. Setengah agen pengecai didapati mempunyai kesan 
signifikan ke atas kualiti pelet. Tambahan pula, proses pengecaian dan pemelarutan 
yang cepat telah diperolehi daripada pelet yang mengandungi minyak kacang soya, 
yang mencadangkan potensi minyak kacang soya sebagai agen pengecai dal3.m 
bentuk dosej petet. Walau bagaimanapun, apabila dua model drug yang berbeza 
keterlarutan air, iaitu paracetamol dan artemisinin, dimasukkan secara berasingan 
ke dalam formulasi-formulasi yang mengandungi minyak kacang soya dan 
dibandingkan, perbezaan dalam ciri-ciri fizikal pelet seperti pengecaian dan 
pelepasan drug in vitro didapati. Pelet-peler yang mengandungi artemisinin tidak 
mengecai serta menunjukkan kadar pemelarutan yang lebih perlahan berbanding 
dengan pelet yang mengandungi diclofenac sodium ataupun paracetamol, yang 
mempunyai keterlarutan air yang lebih tinggi. Oleh kerana sediaan yang 
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pemelarutan ciri-ciri pelepasan tertahan, ini membuktikan bahawa minyak kacang 
soya gagal bertindak sebagai agen pengecai dengan kehadiran artemisinin, iaitu 
suatu drug yang tidak larut air. Daripada kajian ini, terbukti bahawa kedua-dua 
produk pelet.bersfera konvensional dan pelepasan tertahan boleh disediakan melalui 
teknik ekstrusil sferonisasi. 
Penilaian in vivo sediaan yang mengandungi artemisinin dalam lima subjek manusia ;.1 
yang sihat menghasilkan profil kepekatan plasma lawan masa yang seragam serra 
menunjukkan penyerapan yang perlahan dan kadar yang tertahan. Lagipun, sediaan 
terse but menunjukkan tahap penyerapan yang setara dengan sediaan ampaian 
berair. Kepekatan drug dalam plasma ditentukan melalui kaedah HPLC. Suatu 
korelasi yang memuaskan telah diperolehi antara pengukuran kadar pemelarutan in 
vitro dengan keputusan farmakokinetik in vivo. 
1.1 Oral Sustained Release Dosage Forms 
1.1.1 Origins And DeYelopments 
Oral administration remains the principal 'route for systemic delivery of drugs 
because of its convenience to the patients. The ideal drug product is one which 
when given via a multiple dose regimen, will attain steady state levels rapiuly with 
mlI11mUm fluctuations lI1 peak-trough drug concentration. Unfonunately, 
conventional dosage forms can only partially fulfil this therapeutic goal. 
hcqUt.:lltly, tht.:rapcutic failures can be attributed to poor patient compliance. An 
inconvenient dosing regimen may be a possible cause for the failure of drug 
therapy. 'When the regimen is reduced from more than three times daily to twice or 
once daily, patient compliance may improve. However, once a day dosing with 
conventional dosage forms tends to produce big fluctuations between peak and 
trough levels. Therefore, an ideal dosage form will be one that releases its drug 
gradually, preferably at a constant rate, such that relative unifoffi1 drug levels are 
attained.~ :This is particularly important when the drug possesses a narrow 
therapeutic index. Thus, sustained release dosage forms were designed to deliver 
drug in this manner to maintain a uniform drug blood levels within the therapeutic 
range for prolonged periods of time (Wilson & Washington, 1985). This may also 
help to reduce the frequency of dosing, thereby improving patient convenience and 
compliance. A variety of terms has been used to describe these dosage forms, such 
as sustained release, controlled release and prolonged release (Longer & Robinson, 
1985). 
One of the earliest attempts to control drug release in the gastrointestinal tract was 
the use of enteric coating. The concept of enteric coating for pharmaceutical 
products was introduced more than a century ago (Ellis et al., 1976, Helfand & 
\""""-VVYvJ.J., .... ,,"--'_/. __ _ 
primarily to delay drug release until emptying from the stomach had occurred. In 
contrast, modern sustained 'release or controlled release preparations are designed 
to release the drug gradually over a great length of the gastrointestinal tract. 
Controlled release preparations have a number of therapeutic advantages over 
conventional dosage forms. One of the major advantages of using sustained release. 
products is in reducing the frequency of dosing leading to better patient compliance 
and convenience. Such dosage fonns will be most useful for drugs that are used 
chronically and must be administered several times a day. It has been shown that 
sustained release products help to minimize or eliminate the possibility or i'orgottc;n 
doses since less frequent dosing is required (Longer & Robinson. 1985). Another 
advantage of sustained release products, as mentioned previously, is in attaining 
smaller fluctuations in peak-trough levels within the therapeutically desirable range 
and thus improves treatment efficiency, especially with drugs having narrow 
therapeutic indices (Mutschler & Langguth, 1985). Some suswined release devices 
'such as those that are microencapsulated may be suitable for drugs (example 
\ ' 
indomethacin) which irritate the gastrointestinal mucosa (Ro\ve, 1983). Reduction 
. . 
in gastrointestinal irritation and toxicity is also made possible by controlling the 
rate of drug release, thereby avoiding high drug concentrations with the mucosal 
wall. From studies with lithium, it has revealed that conventional preparations 
generally produced more nausea (gastrointestinal irritation) than the slow-release 
forms (Gibaldi, 1977). 
Since the 1950s and 1960s, a variety of sustained release dosage forms were 
developed. Many methods were used to control the drug release, such as coating of 
drug pellets with varying thicknesses, embedding the drug in a porous plastic 
matrix, binding the drug to ion-exchange resins and using drug complexes with 
colloidal materials. Nevertheless, many problems were encountered with these 
assessed. Thus, bioavailability studies were added as one of the criteria for 
effective drug product development. 
The development of improved analytical techniques together with advancement in 
biopharmaceutics and pharmacokinetics in the 1960's and 1970's have led to 
improvements in the design and evaluation of sustained release dosage fomls. As a 
result, a modern generation of sustained release products were developed. The use 
of chemical modifications for sustained drug delivery, such as using a p rocl rug , is 
another approach to help increase bioavailability. A prodrug is formed by adjusting 
the parent compound's physicochemical properties so that absorption is incre~lsed 
and is bioreversibly converted to the active drug slowly after absorption. It is this 
prolongation of the duration of action of the parent compound that results in a 
sustained-reiease effect. Example of prodrugs are long-chain esters of steroidal 
compounds (KennerIey, 1983). 
Sustained release products can be formulated as single- or multiple-unit dosage 
, 
; . 
fonns. Single-unit systems may be erodable, or non-disintegrating, typically based 
on matrix release or osmotic deliverv. Materials that are commonlv used in matrix 
- -
fommlations are insoluble plastics (example methylacrylate - methyl methacrylate), 
hydrophilic polymers (example sodium carboxymethylcellulose), and fatty/waxy 
compounds sllch as glyceryl stearate. Abbott's Gradumet tablet and Ciba Geigy's 
LOIlWb tablet are examples of dosage fonns utilizing plastic and wax matrices. 
respectively (Longer & Robinson, 1985). 
In the plastic matrix system, the drug is dissolved slowly by the permeating 
gastrointestinal fluids and leached out from the system along the cracks and 
capillary channels ata rate that is dependent on several factors including the 
porosity of the inert matrix and drug solubility. The release rate generally 
j." 
described by Higuchi (1963). The principle controlling drug release by hydrophilic 
matrix is that on exposure to aqueous fluids the hydrophilic gum rapidly hydrates 
forming a gel layer at the tablet surface where soluble drug diffuses through thl.; 
swollen matri~. When the hydrated matrix is worn away by external agitation, drug 
is released by matrix erosion (Colbert, 1974). The wax and lipid matrix system is 
based on surface erosion mechanism whereby the tablet does not disintegrate but 
simply erode in the gastrointestinal tract. Drug release is due to tablet erosion 
where the release rate declines with surface area (N otari, 1987). 
Oral osmotic dosage form has been introduced relatively recently as a Jate-
controlled dosage form for many drugs. In this system as described by Theeuwes 
(1975), the drug reservoir is surrounded boy a rigid rate-controlling membrane 
which is semi-permeable with respect to water. Uptake of water through the rigid 
membrane at a controlled rate, will cause the device to deliver, via an orifice in the 
membrane, a volume of saturated drug solution equal to the volume of water 
imbibed. The release rate of the dissolved drug is constant provided an excess solid 
\' 
remains within the device. Since the mechanism of this system is based on osmotic 
pressure, the system delivers drug at a rate that is essentially independent of 
external conditions such as gastrointestinal pH. Examples of some marketed 
products utilizing osmotic delivery system are Acutrim (phenylpropanolamine), the 
appetite suppressant from Ciba Geigy, and Osmosin (indomethacin), the NSAID 
from Merck Sharp & Dohme. However, due to reported serious adverse reactions, 
the product Osmosin was withdrawn from the market in 1983 (Beckett, 1983; 
Ganderton, 1985; Notari, 1987). 
As controlled-drug delivery systems become popular, multiple-units dosage form 
design and development also increased substantially. A multiple-units dosage form 
is a system of numerous pellets or granules of drug filled in a hard gelatin capsule 
Theo-Our tablets from Astra). These subunits combine to give the overall desired 
controlled drug release of the dose. For example, the pellets in a capsule can be 
coated with different thicknesses of a slowly soluble substance, such that a 
relatively constant rate of drug release is produced when the coats are dissolved at 
different periods of time. This is because the dissolution of the coats is a fUllction 
of its thickness. Spansule capsules, which was commercially introduced by Smith 
Kline & French in the 1950's, was based on this principle (Notari, 1987). 
Alternatively, the drug pellets can be coated with a non-soluble polymer to control 
the drug release. Both the thickness and the porosity of the coat are important 
considcrallOlls ill such a design (Yucn el al., 1993). 
1.1.2 .Multiple-Units Versus Single-Units Dosage Forms 
Oral controlled-release products can be formulated as single-unit or multiple-units 
dosage form. Single-unit preparations such as matrix tablets, consist of a single 
nondisintegrating unit which 
. 
releases drua :::> during passage througb tbe 
gastroinle~tinal tract, whereas multiple-unit preparations such as coated pellets are 
usually filled in a hard gelatin capsule. In the gastrointestinal tract the clpsule 
dissolves and the units are released. Pelletized products, of late, are becoming 
more popular in the pharmaceutical industry because they appear to have some 
advantages over the single-unit dosage forms. 
In the case of single-unit preparations, gastric emptying is essentially a random 
process with a large intra- and inter-subject variation, while a multiple-units dosage 
form has the advantage of emptying gradually from the stomach (Bechgaard, 
1982). Pellet dosage forms of diameter less than 1mm are said to be sufficiently 
small to pass through the pylorus even when the sphincter is closed, and that they 
can be widely dispersed throughout the gastrointestinal tract, resulting in reduced 
al., 1985). 
Multiparticulate devices may be well distributed over the intestinal region and since 
each subunit releases the drug slowly, high local concentrations of drug are seldom 
produced, thus minimizing the risks of local irritation or damages on the intestinal 
mucosa (Beckett, 1983). Moreover, if drug release from some subunits is 
impaired, only a small proportion of the dose is affected. Therefore, the danger of 
incomplete release of drug cop.tent is reduced. 
Another potential advantage of multiple-units dosage furms is that pelkts 
containing different active substances can be readily mixed and filled into a 
capsule. This enables incorporation of chemically incompatible drugs in one single 
dosage form. Also, in the case of multiple pellet systems, a combination of pellets 
of different coatings of the same drug can be used to obtain different rates of drug 
release in order to provide the desired sustained action (Ghebre-Sellasie, 1989) . 
. 
\ : 
1.1.3 PhYsiological Factors Influencing BioavailabiIitv 
The gastrointestinal tract may be divided into three major segmems : the stomach. 
the small intestine, and the large intestine or colon. Among the physiological 
factors that may intluence the release of drug from some oral sustained release 
dosage forms are gastric emptying time, intestinal motility, variations in 
gastrointestinal pH and surface area, to name a few. 
The gastrointestinal tract possesses important regions of variation with respect to 
absorption. The small intestine has the greatest available surface area and hence 
represents the segment of the gastrointestinal tract with the highest capacity for 
drug absorption. Therefore, any factor which affects intestinal motility can affect 
;.~ 
drug slowly. In contra':. the available surface area of both the stomach and the 
colon is srgnificantly·:-.:~lll, and for most drugs, absorption through the gastric 
mucosa and from the :Jlon is far slower than that occurring from the small 
intestine. The colon m~:. serve as an absorption site for dosage forms which release 
drug slowly, for examp:~' sustained release products or enteric-coated tablets, only 
if the. drug molecules l2.:l be absorbed in this region. Generally, if a considerabk 
fraction of a dose reach~.:; this region, it is likely that incomplete absorption of the 
drug results (Gibaldi, IS-7; Mayersohn,1979; Wilson & Washington, 1985). 
Variation in the bioaval· .. l.bility of sustained release formulations can arise due to 
variable gastrointestinal :ransit times which affect the time period over which drug 
can be absorbed. The or, 'caecal transit time of a dosage form is highly dependent 
on gastric emptying. He::ce, by prolonging the gastric residence, the overall transit 
time of a dosage form .:an therefore be extended. If the drug dissolves in the 
stomach contents, drug ",lution will then pass in an unimpeded manner to the small 
intesti~e: for subsequem absorption at the optimal site. Gastric emptying of 
phar:naceutical dosage f,'rms is a process influenced by numerous factors such as 
diet, emotional state, ;,osture of the subject and the type of dosage fom1 
administered (Kennerb, 1983; Khosla & Davis, 1987). Conversely, small 
intestine transit is not aU;:cted by these factors and it has been shown that the mean 
transit ti111e of insoluble ~ranules through this region in humans is estimated to be 
about 4 hours (Gibaldi, 1977; Christensen et al., 1985). 
Various attempts have bc·=n made to control or influence the gastrointestinal transit 
time of slow release prc!,::lrations such as altering particle or pellet size and density, 
using of bioadhesive t,olymers and intragastric floating systems (Wilson & 
Washington, 1985; Kho~la & Davis, 1987; Blok et al., 1991). 
investigated and conflicting results have been reported. Bechgaard & Ladefogcd 
(1978) revealed that an increase in pellet density from 1.0 to 1. 6g/cm3 significantly 
delayed average transit times in the small intestine in ileostOmy subjects. However. 
the diameter·of pellets, increased from 0.5 to 1.5mm was of minor significance. 
Similarly, recent studies performed by Devereux et al. (1990) reponed that the 
gastric emptying of the heavy pellets of density 2.8g/cm3 as compared to the light 
pellets of density l.Sg/cm3 was extended in both the fed and fasted state. 
Nevertheless, there was no significant difference in the small intestine transit time. 
In contrast, studies by Kaus et al. (1984) have failed to show significant differences 
due to density in the transit rate through the small intestine in normal subjects 
between two specific gravities investigated; one with a range 1.01 to 1.05, whilst 
the other 1. 59 to 1. 63. Additionally, no influence from pellet density (densities 
between 0.94 and 1.96g/cm3) was observed on gastrointestinal transit in ileostomy 
subjects by Bechgaard et al. (1985). 
1.1.4 }n~ Vitro-In Vivo Drug Correlation 
The development of controlled release dosage fomls necessitates the need for 
appropriate standard quality control tests to evaluate some of the finished drug 
product specifications in good manufacturing practice. The documented .inability of 
disintegration tests to provide an index of bioavailability has resulted in the 
introduction of in vitro dissolution tests for sustained release products. Since 1960, 
many satisfactory in vitro-in vivo correlations were reported. Thus, dissolution 
testing became a convenient and reliable in vitro method to assess the release 
characteristics of a drug formulation. 
Development of the in vitro dissolution test method should take into physiological 
considerations so that consistent in vivo-in vitro correlations are obtained. The 
(1982) are based on its ability to discriminate between subtle variability of 
dissolution characteristics, reproducibility of data, as well as its flexibility to 
accommodate a wide variety of drug products. 
According to Nelson & Miller (1979), currently, there are two distinct types of 
disso~ution test models, the stirred vessel and the flow-through column. The fonner 
method is characterized by a relatively large volume of dissolution medium with 
minimal liquid exchange and agitation is accomplished by stirring the liquid or by 
motion of the vessel. Conversely, the characteristic of the latter type is a relatively 
small dissolution cell by which the dissolution medium is replenished with' fresh 
solvent at constant rate and without additional agitation. 
There are a number of operating variables that must be considered when 
performing dissolution methodology, regardless of the type. One of the major 
factors is the type 3.nd intensity of agitation. Stirring rates must be controlled, and 
specifications differ between drug products. Secondly, tbe temperature of the 
\ : 
dissolution medium must be controlled and temperature variations should be 
avoided. Most dissolution test are perfomled and maintained at 37°C (±0.5°C). A 
third consideration is the nature of the dissolution medium. The dissolution medium 
should be aqueous and should not be saturated by the drug in order to simulate the 
in vivo sink condition. Usually. a volume of medium larger than the amount of 
solvent needed to completely dissolve the drug is used so that the drug 
concentration in the in vitro dissolution medium never exceeds 10-15 % of 
saturation. Commonly employed aqueous systems include phosphate buffer, dilute 
hydrochloric acid, simulated gastric and intestinal fluid, and distilled water. 
Surface-active agents may be added to the dissolution medium of specialized drug 
products to simulate bile function in the gastrointestinal tract (Pernarowski, 1974; 
Gibaldi, 1977; Abdou, 1985). 
I' . 
The United States Pharmacopeial (USP) provides several official in vitro methods 
for testing controlled release dosage form dissolution. Examples of stirred-vessel 
types of dissolution apparatus are the rotating basket method (apparatus 1) and the 
paddle method (apparatus 2). The mode of operation for both methods is easily 
adapted to automated version. The column method of dissolution testing is not as 
widely used as the stirred-vessel method, example the flow-through cell dissolution 
apparatus. This flow-through cell method, which is considered as apparams 4 in 
USP 23, can be readily automated as well. The rotating bottle apparatus, a 
nO/1official method for determining dissolution rate of pharmaceutical preparati\!Ds 
with controlled-release characteristics, has been included in the National Formulary 
(NF) XIII. This method, however, has become less popular owing to its manual 
procedure, . a main disadvantage, since automatic testing is highly desirable 111 
sustained release preparations (Nelson & Miller, 1979; Hanson, 1982). 
Comparisons between in vitro release or dissolution rates and the in vivo absorption 
data are l;lseful to validate in vitro dissolution model systems. It is advisable that in , . . 
vivo ~tudies be conducted on human subjects as there are fundamental differences 
in overall physiology between experimental animals and man. In vivo-in vitro 
correlations can be based on clinical observations or response, plasma or urine 
concentration data, or absorption kinetics. Most of the bioavailability evaluations 
are based on drug levels in plasma or urine which give a better objective 
infonnation on bioavailability of drugs in humans. 
When perfonning an in vivo bioavailability study, a reference' fonnulation IS 
necessary against which all other fonnulations of the drug are compared. The 
reference fonnulation should be in its most bioavailable forrl1ubtioIl, that is, 
solution or suspension. The study can also be evaluated relative to intravenous (IV) 
administration of the drug for which instantaneous and complete bioavailability is 
;.' 
i.,~ .. ,".:::,~,~,~\'.:,',','.,',' .  "'.;":' ..'.,: .. ',. assumed. Alternatively, the use or an esraOllsneu m1l11cUlalC'relea~ie lUIIllLllclLlUIl • : which already has valid scientific and clinical data can also be acceptable. The in ~~' vivo perfofD1ance of these formulations are compared by examining their 
,. corresponding blood··level profiles. In addition, the bioavailability data of the drug 
f J,.. :l::~: :i::::V:;~~:~:::: :::::::~a~elt:"::V::ti:::~::e::::~:~ ::::g~U;::~:< 
I bioequivalent to a reference standard sustained release preparation, which may be 
~ an original patent or currently marketed dmg product, which has undergone 
} {~-
extensive clinical testing. 
There are cases where in vitro release or dissolution rates may not reflect in 'vivo 
absorption rates. Some dosage forms do not demonstrate bioavailabiiity and 
dissolution correlation and this may be attributable to several in vivo factors such as 
variable gastric emptying and intestinal transport rate and differences in clinical 
response shown by sick patients and normal, healthy human volunteers (Swarbrick. 
1970). S ingle-dose studies are still commonly employed to obtain in vivo data and 
is usualty: performed in healthy human subjects. Nevertheless, in drug product 
develoyment, dissolution testing is :;till a very useful tool for evaluating a potential 
dmg fOfD1ulation prior to performing an in vivo bioavailability study. 
1.2.1 Introduction 
Malaria is a major health problem in many parts of the world, the most 
hyperendemic malarious areas being ;:1 the tropics. The infection occurs through 
the bite of an infected female anopheles mosquito (the disease vector). The 
emergence of chloroquine-resistant falciparum malaria has been occurring on a 
global scale, of late. Chloroquine, the most widely used antimalarial drug, has in 
the past been considerably effective in the treatment and control of malaria due to 
Plasmodium Jalciparwn, the species which caused 85 % of world malaria infection 
accordillg tu World Health Organisation (Luo & Shen, 1987). Recently, this 
parasite has also developed resistance to other available antimalarial drugs such as 
quinine, pyrimethamine-sulfadoxine (Fansidar), and even to mefloquinc. the 
effective long-acting quinine analogue (Li et al., 1984). In view of the increasing 
development of multidrug-resistant strains of Plasmodium jalciparum, novel 
antimalarial drugs effective against resistant strains are urgently needed to 
overcome this potential serious problem. 
One suet drug IS the natural product artemisinin, also called qinghaosu in 
Chinese, which is now a leading and promising compound of a new class of anti-
malarial drugs. Artemisinin is a constituent of the Chinese medicinal plant 
Artemisia annUQ Linn. (Qinhao), where the genus Artemisia belongs. to the 
COlllpositac ramily (Aslcraccac). The crude extract of this herb has been used for 
many centuries in China as :l treatment for febrile illness. Later, it bec:lme evident 
that its antipyretic property is confined to malaria therapy. The active principle 
artemisinin was isolated and defined in 1972 by Chinese scientists and showed to 
have a unique chemical structure, unlike most other antimalarial drugs. It is a 
sesquiterpene lactone that bears a peroxide group (Figure 1.2), a functionality rare 
in natural products but which is essential for expressing antimalarial activity 
(Titulaer e tal., 1990; Titulacr et al., 1991). However, extracts from other species 
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Figure 1.2: Structure of artemisinin 
Artemisinin is an effective antimalarial agent against vivax malaria as well as both 
chloroquine-sensitive anu chloroquine-resistant falciparum malaria. It is active 
against plasm?dia of the erythrocytic phase, especially in their early development 
cycle. This rapid acting blood schizontocide destroys asexual parasites, thus 
arrestir:g trophozoite development at the small ring stage. These characteristics 
enable it to treat critically ill malaria patients with high parasitaemia, since it has a 
rapid rate of parasitaemia clearance and inhibitory effect on parasite uevelopmem 
which make it a potent and superior drug for the treatment of cerebral rnalarLl 
resistant to other well-known antimalarials. This fatal complication is an advanced 
fonn of Plasmodium Jalciparum malaria, usually presenting as delirium or coma. 
that can occur when more than 5 % of erythrocytes are infected with parasites (Li er 
al., 1984; Klayman, 1985; Luo & Shen, 1987; Titulaer et al .. 1991). 
Artemisinin seems to be less liable to induce drug resistance in Plasmodia. Until 
now no resistance to this drug has been described in patients, but to date. it is still 
. \ . 
not readily available. There has been no marked evidence of cross-resistance 
betweell artemisinin and other antimalarial agents. This new compound has 
relatively low toxicity. The acute toxicity seems to be negligible or considerably 
less than that of chloroquine. It appears to be remarkably well tolerated in man, 
even to women in middle and late stage of pregnancy (16-38 weeks) with malaria 
where they were found to be effectively treated without adverse effects. 
Nonetheless, safety for use in pregnant women and nursing mothers has not been 
established. Embryotoxic effects of the drug has been reported in animal studies 
(Qinghaosu Antimalaria Coordinating Research Group, 1979; Klayman, 1985; Fu 
et at., 1990; Titulaer et at., 1991). 
potentiated the action of 3rtemisinin against both chloroquine-sensilive and 
chloroquine-resistant strains of Plasmodium jalciparwn ill vitro; whilst primaquine 
showed potentiation only against the resistant strains. By comparison, antagonism 
was found for the combination of artemisinin with chloroquine and pyrimethamine. 
The interactions observed correspond with those found in rodent malaria in vivo 
and may ~hus be ascribed to a direct action on the parasite and not merely due to 
effects on the drug pharmacokinetics in the host (Chawira et ai., 1987). In order to 
prevent or delay the emergence of parasite resistance, it is found necessary to use 
'. 
drug combinations. A combination of met10quine and artemisinin is recommended 
by World Health Organisation in the treatment of uncomplicated falciparum 
malaria in cases where all the standard antimalarials fail because of resistance 
(World Health Organization, 1993). Interactions of artemisinin with other drugs to 
date,· have not been reported (Hien & White, 1993). 
1.2.2 i'vlechanism Of Action 
. \ . 
. . 
The ~reclse mechanism of action of artemisinin is not fully understood btl[ acts 
differently in mode and site of action from other antimalarial drJgs. The minimal 
inhibitory concentration for this drug is estimated to be 1O-7M in vitro (Klayman, 
1985). Studies revealed that artemisinin does not interfere with the folic acid 
metabolism of the malaria parasites (Luo & Shen, 1987; Titulaer et al .. 1991). 
It has been suggested that the action of artemisinin may involve increase of oxidant 
stress on the infected erythrocytes. Although the unique peroxide moiety in its 
structure is vital for its antimalarial activity, no evidence has been obtained on its 
possible role in the action. Cessation of protein synthesis in Plasmodium 
jalciparum, possibly due to oxidative damage to the protein synthesis machinery, 
may be one of the prime targets of the drug action. According to studies performed 
;.< 
